References
- Liu L, Yang Y, Guo Q, Ren B, Peng Q, Zou L, et al. Comparing hypofractionated to conventional fractionated radiotherapy in postmastectomy breast cancer: a meta-analysis and systematic review. Radiat Oncol. 2020;15(1):17. DOI: 10.1186/s13014-020-1463-1
- Kadam SS, Tripathi P, Jagtap R, Kapoor R, Kadam T, Bhandarkar P, et al. Modified Radical Mastectomy vs Breast-Conserving Surgery: Current Clinical Practice in Women with Early Stage Breast Cancer at a Corporate Tertiary Cancer Center in India. Indian J Surg Oncol. 2022;13(2):322-8. DOI: 10.1007/s13193-021-01457-8
- Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, et al Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol. 2021;32(8):1015-24. DOI: 10.1016/j.annonc.2021.05.353
- Horisawa N, Adachi Y, Takatsuka D, Nozawa K, Endo Y, Ozaki Y, et al. The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status. Breast Cancer. 2022;29(2):234-41. DOI: 10.1007/s12282-021-01303-3
- Fleming GF, Pagani O, Regan MM, Walley BA, Francis PA. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2022;33(6):658. DOI: 10.1016/j. annonc.2022.03.003
- Chen B, Sang Y, Song X, Zhang D, Wang L, Zhao W, et al. Exosomal miR-500a-5p derived from cancer-associated fibroblasts promotes breast cancer cell proliferation and metastasis through targeting USP28. Theranostics. 2021;11(8):3932-47. DOI: 10.7150/thno.53412
- Peng X, Zhang Z, Mo Y, Liu J, Wang S, Liu H. Bioinformatics Analysis of Choriocarcinoma-Related MicroRNA-Transcription Factor-Target Gene Regulatory Networks and Validation of Key miRNAs. Onco Targets Ther. 2021;14:3903-19. DOI: 10.2147/OTT.S311291
- Ghasabi M, Mansoori B, Mohammadi A, Duijf PH, Shomali N, Shirafkan N, et al. MicroRNAs in cancer drug resistance: Basic evidence and clinical applications. J Cell Physiol. 2019;234:2152-68. DOI: 10.1002/jcp.26810
- Frontiers Editorial Office. Retraction: microRNA-155 Modulates Hepatic Stellate Cell Proliferation, Apoptosis, and Cell Cycle Progression in Rats With Alcoholic Hepatitis via the MAPK Signaling Pathway Through Targeting SOCS1. Front Pharmacol. 2022;12:840009. DOI: 10.3389/fphar.2021.840009
- Wen Q, Wang Y, Pan Q, Tian R, Zhang D, Qin G, et al. MicroRNA-155-5p promotes neuroinflammation and central sensitization via inhibiting SIRT1 in a nitroglycerin-induced chronic migraine mouse model. J Neuroinflammation. 2021;18(1):287. DOI: 10.1186/s12974-021-02342-5
- Danza K, Porcelli L, De Summa S, Di Fonte R, Pilato B, Lacalamita R, et al. The ERRα-VDR axis promotes calcitriol degradation and estrogen signaling in breast cancer cells, while VDR-CYP24A1-ERRα overexpression correlates with poor prognosis in patients with basal-like breast cancer. Mol Oncol. 2022;16(4):904-20. DOI: 10.1002/1878-0261.13013
- Zhang S, Liu X, Liu J, Guo H, Xu H, Zhang G. PGC-1 alpha interacts with microRNA-217 to functionally regulate breast cancer cell proliferation. Biomed Pharmacother. 2017;85:541-8. DOI: 10.1016/j.biopha.2016.11.062
- Hu X, Li T, Wang B, Zhang J, Yu X, Shao Z. Comparison of 4th ESOESMO international consensus guidelines for advance breast cancer and Chinese anti-cancer association committee of Breast Cancer Society guideline. Breast. 2019;45:36-42. DOI: 10.1016/j. breast.2019.02.009
- Moldovan JB, Wang Y, Shuman S, Mills RE, Moran JV. RNA ligation precedes the retrotransposition of U6/LINE-1 chimeric RNA. Proc Natl Acad Sci U S A. 2019;116(41):20612-22. DOI: 10.1073/pnas.1805404116
- Grabher BJ. Breast Cancer: Evaluating Tumor Estrogen Receptor Status with Molecular Imaging to Increase Response to Therapy and Improve Patient Outcomes. J Nucl Med Technol. 2020;48(3):191-201. DOI: 10.2967/jnmt.119.239020
- Xie X, Li H, Wang C, Li W, Xie D, Li M, et al. Effect of modified radical mastectomy combined with neo-adjuvant chemotherapy on postoperative recurrence rate, negative emotion, and life quality of patients with breast cancer. Am J Transl Res. 2022;14(1):460-7.
- Finn RS, Boer K, Bondarenko I, Patel R, Pinter T, Schmidt M, et al. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18). Breast Cancer Res Treat. 2020;183(2):419-28. DOI: 10.1007/s10549-020-05755-7
- Ding Y, Wu W, Ma Z, Shao X, Zhang M, Wang Z. Potential value of MicroRNA-21 as a biomarker for predicting the prognosis of patients with breast cancer: A protocol for meta-analysis and bioinformatics analysis. Medicine. 2021;100(22):e25964. DOI: 10.1097/MD.0000000000025964
- Wu K, Feng J, Lyu F, Xing F, Sharma S, Liu Y, et al. Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer. Nat Commun. 2021;12(1):5196. DOI: 10.1038/s41467-021-25473-y
- Murugesan M, Premkumar K. Integrative miRNA-mRNA functional analysis identifies miR-182 as a potential prognostic biomarker in breast cancer. Mol Omics. 2021;17(4):533-43. DOI: 10.1039/D0MO00160K
- Bajaj R, Tripathi R, Sridhar TS, Korlimarla A, Choudhury KD, Suryavanshi M, et al. Prognostic role of microRNA 182 and microRNA 18a in locally advanced triple negative breast cancer. PloS One. 2020;15(11):e0242190. DOI: 10.1371/journal. pone.0242190
- Khalighfard S, Alizadeh AM, Irani S, Omranipour R. Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients. Sci Rep. 2018;8:17981. DOI: 10.1038/s41598-018-36321-3
- Wang F, Wang J, Zhang H, Fu B, Zhang Y, Jia Q, et al. Diagnostic value of circulating miR-155 for breast cancer: a meta-analysis. Front Oncol. 2024;14:1374674. DOI: 10.3389/fonc.2024.1374674
- Hamidi AA, Zangoue M, Kashani D, Zangouei AS, Rahimi HR, Abbaszadegan MR, et al. MicroRNA-217: a therapeutic and diagnostic tumor marker. Exp Rev Mol Diagn. 2022;22(1):61-76. DOI: 10.1080/14737159.2022.2017284
- Fahad Ullah M. Breast cancer: current perspectives on the disease status. In: Breast cancer metastasis and drug resistance: challenges and progress. 2019; pp. 51-64. DOI: 10.1007/978-3-030-20301-6_4
- Song SE, Cho KR, Cho Y, Kim K, Jung SP, Seo BK, et al. Machine learning with multiparametric breast MRI for prediction of Ki-67 and histologic grade in early-stage luminal breast cancer. Eur Radiol. 2022;32(2):853-63. DOI: 10.1007/s00330-021-08127-x
- Chen Y, Wu N, Liu L, Dong H, Wu C. Correlation between microRNA-21, microRNA-206 and estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 in breast cancer. Clin Biochem. 2019;71:52-7. DOI: 10.1016/j. clinbiochem.2019.07.002
- Kalinina T, Kononchuk V, Alekseenok E, Obukhova D, Sidorov S, Strunkin D, et al. Expression of estrogen receptor-and progesterone receptor-regulating microRNAs in breast cancer. Genes. 2021;12(4):582. DOI: 10.3390/genes12040582